Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2018-07
-
Thermal Shift Assays for Ligand Discovery in Bacterial Senso
2026-06-09
This review highlights how thermal shift assays (TSA) have enabled the identification of ligands for diverse bacterial sensor proteins. The paper details methodological advances, reliability considerations, and the importance of accurate ligand screening for understanding bacterial signaling, with relevant implications for drug discovery and pathway analysis.
-
Strategic Advances in Protease Inhibition for Translational
2026-06-09
This thought-leadership article unpacks the mechanistic significance of protease inhibition and connects it to actionable strategies for translational researchers. Drawing on recent peer-reviewed findings and the capabilities of the DiscoveryProbe™ Protease Inhibitor Library, we bridge biological rationale, experimental validation, and clinical relevance. The result is a nuanced, evidence-backed roadmap for accelerating discoveries in apoptosis, cancer, and infectious disease research, setting a new standard beyond conventional product overviews.
-
CPI-613 in Tumor Cell Metabolism Studies: Advanced Protocols
2026-06-08
CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) unlocks new frontiers in apoptosis assays and tumor metabolism studies by targeting mitochondrial vulnerabilities unique to cancer cells. This guide delivers advanced workflows, troubleshooting strategies, and actionable insights for translational researchers aiming to dissect chemoresistance and metabolic reprogramming with APExBIO’s validated compound.
-
DiscoveryProbe Protease Inhibitor Library: Applied Screening
2026-06-08
The DiscoveryProbe Protease Inhibitor Library accelerates breakthrough research in protease activity modulation, enabling high-throughput and high-content screening with unmatched compound diversity and validation. Its precise, automation-ready format empowers robust apoptosis, cancer, and infectious disease investigations, while peer-reviewed workflows and troubleshooting guidance ensure reproducibility and actionable insights.
-
Carbohydrate-Decorated Nanoparticles Enable Macrophage-Targe
2026-06-07
This study systematically investigates biodegradable nanoparticles, decorated with various carbohydrates, for targeted gene delivery into macrophages. The findings highlight how surface carbohydrate composition significantly enhances cellular uptake and transfection efficiency, offering a promising strategy for precise gene regulation in inflammatory and disease microenvironments.
-
Protease Inhibition Impairs Light-Induced Stomatal Opening i
2026-06-06
This study introduces a chemical screening approach to uncover protease inhibitors that modulate blue light-induced stomatal opening in Commelina benghalensis. By identifying specific inhibitors and dissecting their effects on guard cell signaling, the work advances understanding of protease activity in plant physiology and provides methodological guidance for targeted chemical biology studies.
-
GPR30 in Spinal CCK+ Neurons Drives Neuropathic Pain Signali
2026-06-05
This study identifies the G protein-coupled estrogen receptor GPR30 in spinal cholecystokinin-positive (CCK+) neurons as a critical modulator of neuropathic pain. Targeted inhibition of GPR30 reverses pain sensitization after nerve injury, providing new mechanistic insight and a potential therapeutic target for pain research.
-
Fluorouracil (Adrucil) in Cancer Research: Mechanisms and Im
2026-06-05
Explore how Fluorouracil (Adrucil) advances cancer research by inhibiting DNA replication and modulating the tumor immune microenvironment. This article provides a deep dive into its molecular action and unique insights from recent immuno-oncology breakthroughs.
-
Translating Mechanistic Insights into Oncology Breakthroughs
2026-06-04
Explore how the DiscoveryProbe™ Anti-cancer Compound Library (SKU: L1023) accelerates translational research by bridging molecular mechanisms, high-throughput screening, and strategic pathway targeting. Drawing on recent advances in overcoming endocrine resistance in breast cancer, the article provides practical, evidence-backed guidance for deploying compound libraries to unlock new therapeutic avenues.
-
dKeap1 Nuclear Condensates: Mechanisms of Oxidative Stress R
2026-06-04
This study reveals that Drosophila Keap1 (dKeap1) assembles into stable nuclear condensates following oxidative stress, mediated by specific protein domains and intrinsically disordered regions. The findings highlight a novel nuclear mechanism for stress-responsive transcriptional regulation and provide a foundation for dissecting Keap1-Nrf2 pathway functions beyond cytoplasmic signaling.
-
Poly-GA–Induced ERK1/2 Activation Drives Tau Pathology in FT
2026-06-03
The reference study uncovers how poly-glycine-alanine (poly-GA) dipeptide repeats associated with C9orf72 mutations promote tau hyperphosphorylation and neuronal cell death through direct ERK1/2 activation in cellular models. Importantly, pharmacological inhibition of ERK1/2 with U0126 attenuates these pathogenic effects, highlighting a mechanistic link and potential therapeutic target in C9orf72-related frontotemporal lobar degeneration.
-
Thiothixene: Typical Antipsychotic Agent Boosts Efferocytosi
2026-06-03
Thiothixene offers researchers a dual advantage: established efficacy in psychotic disorder therapy and a novel, robust enhancement of in vitro macrophage efferocytosis. This guide details protocol optimizations, troubleshooting strategies, and key mechanistic insights that enable translational immunology and neuropsychiatric research workflows.
-
Romidepsin (FK228) in Cancer Research: Protocols & Insights
2026-06-02
Romidepsin (FK228) is a benchmark HDAC inhibitor empowering researchers to modulate epigenetic states, induce cell cycle arrest, and trigger apoptosis across cancer models. This guide delivers actionable protocols, highlights experimental pitfalls, and interprets recent proteomics findings to maximize Romidepsin's impact in applied oncology workflows.
-
Rapamycin (Sirolimus): Precision mTOR Inhibition in Hepatic
2026-06-02
Rapamycin (Sirolimus) empowers researchers to dissect mTORC1-mediated stress pathways and cell death mechanisms in hepatic and metabolic disease models. This article delivers actionable protocols, troubleshooting strategies, and data-driven insights, translating the latest mechanistic breakthroughs into robust assay workflows for advanced mTOR signaling research.
-
Cell-Based HTS for HIV-1 Protease Autoprocessing Inhibitors
2026-06-01
This study presents a validated, cell-based AlphaLISA assay for high-throughput screening of inhibitors targeting HIV-1 protease autoprocessing. The platform enables precise assessment of candidate inhibitors’ efficacy and resistance profiles, offering a robust tool for antiviral drug discovery.